Stephen Basil Thomas serves as Executive at Eliem Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Stephen Basil Thomas has executed 3 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Aug 7, 2025 involved receiving (via award) 100,375 shares valued at $0.
Stephen Basil Thomas currently holds 304,657 shares of Eliem Therapeutics, Inc. (ELYM), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Stephen Basil Thomas has been a net neutral trader of ELYM stock. They have purchased $0 and sold $0 worth of shares.
Stephen Basil Thomas's most recent insider trade was on Aug 7, 2025, when they sold 100,375 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |
| Jun 27, 2024 | ELYM | $0 | Award | 103,907 | $N/A | Discretionary |